135 related articles for article (PubMed ID: 10704656)
1. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1.
Bendz B; Andersen TO; Sandset PM
Thromb Res; 2000 Mar; 97(6):463-72. PubMed ID: 10704656
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
[TBL] [Abstract][Full Text] [Related]
3. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol.
Sandset PM; Larsen ML; Abildgaard U; Lindahl AK; Odegaard OR
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):425-33. PubMed ID: 1932528
[TBL] [Abstract][Full Text] [Related]
4. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum.
Berrettini M; Malaspina M; Parise P; Lucarelli G; Kisiel W; Nenci GG
Am J Clin Pathol; 1995 Apr; 103(4):391-5. PubMed ID: 7726132
[TBL] [Abstract][Full Text] [Related]
5. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase.
Mast AE; Broze GJ
Blood; 1996 Mar; 87(5):1845-50. PubMed ID: 8634431
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
Rao LV; Ruf W
Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
[TBL] [Abstract][Full Text] [Related]
7. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma.
Hubbard AR; Weller LJ; Gray E
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):819-23. PubMed ID: 7865689
[TBL] [Abstract][Full Text] [Related]
8. Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin.
Hansen JB; Svensson B; Sandset PM; Thijssen F
Thromb Res; 2000 Dec; 100(5):389-96. PubMed ID: 11150580
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
10. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
11. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor.
Bognacki J; Hammelburger J
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S65-72. PubMed ID: 7647224
[TBL] [Abstract][Full Text] [Related]
12. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations.
Jeske W; Hoppensteadt D; Fareed J; Bermes E
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S73-80. PubMed ID: 7647226
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition.
Salemink I; Franssen J; Willems GM; Hemker HC; Lindhout T
J Biol Chem; 1999 Oct; 274(40):28225-32. PubMed ID: 10497177
[TBL] [Abstract][Full Text] [Related]
14. Probable regulation of factor VIIa-tissue factor and prothrombinase by factor Xa-TFPI and TFPI in vivo.
Gouin-Thibault I; Dewar L; Craven S; Kulczycky M; Wun TC; Ofosu FA
Br J Haematol; 1996 Dec; 95(4):738-46. PubMed ID: 8982054
[TBL] [Abstract][Full Text] [Related]
15. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor.
Iakhiaev A; Pendurthi UR; Voigt J; Ezban M; Vijaya Mohan Rao L
J Biol Chem; 1999 Dec; 274(52):36995-7003. PubMed ID: 10601255
[TBL] [Abstract][Full Text] [Related]
16. Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface.
Riesbeck K; Dorling A; Kemball-Cook G; McVey JH; Jones M; Tuddenham EG; Lechler RI
Thromb Haemost; 1997 Dec; 78(6):1488-94. PubMed ID: 9423800
[TBL] [Abstract][Full Text] [Related]
17. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway.
Sevinsky JR; Rao LV; Ruf W
J Cell Biol; 1996 Apr; 133(2):293-304. PubMed ID: 8609163
[TBL] [Abstract][Full Text] [Related]
18. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.
Ott I; Miyagi Y; Miyazaki K; Heeb MJ; Mueller BM; Rao LV; Ruf W
Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):874-82. PubMed ID: 10712416
[TBL] [Abstract][Full Text] [Related]
19. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis.
Francischetti IM; Mather TN; Ribeiro JM
Thromb Haemost; 2004 May; 91(5):886-98. PubMed ID: 15116248
[TBL] [Abstract][Full Text] [Related]
20. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor.
Jesty J; Lorenz A; Rodriguez J; Wun TC
Blood; 1996 Mar; 87(6):2301-7. PubMed ID: 8630391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
